Axon / Taser Favorability Statistics 2023

Favorability *******

**** **** ***-****** ** *********** ******** Do *** ****, **** ** ********** 15% ****** * ******* ******* (**% total). ***** ***** **** ********/******** ********, their *** ************ ** * **** positive, +*%.

Weaker ******* **

******* *** **, ****'* *** *****'* net ************ ***** ** -*% ****** +9% ******, **** **** ****** ******* opinion, ** ****.

Most ***********: Don't ****

**** *********** *** *** **** *** Axon/Taser **** ** *** * ******* opinion, **** **** * ******* ** positive *** ******** *****.

• "***** ***** ** ****. *****’* **** or ********** **** **** ******* ** all."
• "* **** ***** *** *** *********** with ****/*****. *'** **** **** ******* via *** **** *******."
• "* **** ** ********** ***** ****. However * *** ***** **** ** a *** ** **** *** ******* that **** ********.... **** **** ** doing ********* *****."
• "***'* *** **** ** *** ***** Axon/Taser. * **** *** *** ***** videos ** *** **** *** *** time *** ****** ** ** * decent ******* ******."
• "* ******* **** *** *** **** of *** ********* ****** *** ********. we **** *** *** * **** to ****** *** ** ***** ** our ******** ****."
• "** **** *** ** ******** **** Axon. ** ******* *** ** **** once ***** **** ******** ******** *** never ***** ****."
• "*'** **** ****, **** **** *******, but **** ** ******** **********"
• "************* * ** *** **** ******** about **** ******* ******."
• "**** **** ** ****. *****'* **** or ********** ***** *********."
• "***** **** **** ** *** **** up ** ** ******."
• "***** **** ** *** *** ********** with ****."
• "** ***'* **** ********** **** ****/*****."
• "* ** *** ******** **** **** company."
• "** **** *** **** **** /*****."
• "**** ***** **** ***** *******."
• "** ********** **** *******."
• "**** *** *********** ****."
• "***** **** ***** ** ****."
• "* **** *** ***** ** ****."
• "** ********** **** ****."
• "* ** *** *** **** *******."
• "**** ***** **** ****."
• "***** ***** ** ****."
• "*****'* **** ****."
• "***** ****, *****."
• "*** ******** ****."
• "*****’* ****."
• "***** ****."
• "*/*" [**].

******* *********** **** **** ****/***** **** not ********* ** ***** *******/******:

• "***** *** *********** ** ** *******, Not ******** **** **** - *** seen ** **** ** *** ***********." (Norway)
• "**** ***’* ****** ******** ** *** market. ***** ********** ** *********, *** we **** ** ****** ********** ******* with ****." (**)
• "******** ******* ****/***** ** *** *** well ***** ** *****, ** ** not **** **** ***** ****."
• "** * ** ***** ** *** UK * ** *** ******** **** this *******."
• "**** ** *** ********* ** **** region." (******** & ******)
• "*** **** ** **é***, ******."
• "*** *** *********."

*******, ****** ******** **** **** **** who ****/***** ****, *** ****** **** not ** *** *** *********** ********:

• "* **** ******* ** *** ***** Axon ** *'* *** ** **** market."
• "** ********** **** ****. * ******* Axon ** *** ** *** ******* business. ** ***'* *** **** *** do ** **** *** *********** ** use ****."
• "* **** ** ***** **** **** part ** *** ********."
• "*** ** **** ******, *** ******** with ****."
• "******** *** ** *****."

Positive: ****** ******** ** ***** ********

***** ********** ********** ******* ****/***** ********, especially ****-**** ******* *** ******** **********.

• "**** **** **** ********. ** ***'* use/sell ****, *** ** ** * lot ** **** **** *** *********** and **** *** *** **** *********** of **** ********. ** **** ** deal **** ********.*** ************ **** ****'* use ** ** ***** ******** **** our *** *******. ***** ******* ** always ****** *******, **** ****** ** are *** * ******** ** ****** for ****."
• "* ***** **** **** **** ****** qualities ** *** ********** *** ******* of ****/*******. ** ** ******** ** control ******** ********* *** **** **** to **** **** **** ***** ** collating **. * **** ***** ***** body **** ******** **** ****** **** good *** ****** ***********."
• "**** ** ****. ** *** **** interview **** ***** *** ****'* **** to ** **** ***** **** *******. They ***'* ****** ****** ************* *** rather **** *** ** *********. **** also *** * ****** ******* *** takes **** ***** *** ****** ** happen ** ******."
• "**** ****** ********* ** ******** **** complement **** *****, **** ******* ***** and * **** *** **** ***** software *****."
• "**** ***** ** ****** *****. ****** also **** ***** (******* ** ******** to ****). * ***'* **** ****** of ***** ******** ** * ***'* do *** *********** ********."
• "** ******* **** *** **** ****, so **** *** ****** *********** *** if *** ** **** **** * don't ***** ***. **** *******, **** support, **** *** ***** *** ******** it."
• "* *****'* **** ***** ******** **********, but *'** **** **** ******** *** I've ******* *** *** ******** **** they **** ****** ** *** *********. They **** ****-*****."
• "*** ******* **** ** ****** *** availability ** ******** ** ****** **** others."
• "**** ***** ** ** *** ******** standard. **** **** ******* ********."

Negative: ******** *********, *** ********

***** ********** ********** **** ***** ***** Axon's ******** *********, *** *** ******* of ********.

• "* **** ****** **** **** ** Agencies **** *** **** ******* ** their ********* *** ********* ** *** footage. * ******* ** ** ******* and ********* ***** *** *** **** go ** ****** *** * ****** support **."
• "* ****** ******* ******* ** ********** to ***** ********* ****** ******* ** non-lethal, *** **** ***** ****** **** their ******* ******** **** *** *** any ****** ** **** *** **** Axon."
• "** *** ****** ********** ** **** of ***** **** ************ ********* *** unfortunately **** *** ******** ******* **** it ***** **** ** *** **** field **** ***** *********** **** *** solution."
• "*** ***** *********** *** *** ****** to *** ******* ** *****. **** have *** *** *********** ****** ****** down. *** ************ ******** *** ***** integrate **** *** **** ***, *** thus * ***** *** **** ***-**** body ****."
• "** **** **** *** *** ***** competing ********. *** **** ** **** used **** *** **** ******** *** not ***** **** ****."
• "********* ******* *** ******** ************ ***** out *** ******** **** ****** *******."
• "**** **** ******. **, ******* ***'* have **** **** ********."
• "*** *** *** ***** *****."

*******

****'* **** ** *********** ***** *********** is *** ********, ***** ***** ****** sales ********, ****** ** *** ***********, with ** ********** *******. *******, ** expect ***** ********* ** *** *********** to ********, ** **** ******** **** standardized ** ****/***** *** ***** ** the ******** *** ***** ****** ** word-of-mouth **************.